NASDAQ · ABOS
Healthcare · Biotechnology
$2.27
Down-$0.12 (-5.29%)
Updated Oct 27, 2026, 2:06 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ABOS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
ABOS closed at $2.27 after 21 trading sessions, down 1.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $2.13 | $2.42 | $1.97 | $2.27 | 1.65M |
| Oct 23, 2026 | $2.05 | $2.05 | $1.895 | $1.98 | 541.79K |
| Oct 22, 2026 | $2.03 | $2.14 | $2.01 | $2.06 | 569.49K |
| Oct 21, 2026 | $2.00 | $2.08 | $1.99 | $2.03 | 397.71K |
| Oct 20, 2026 | $1.78 | $2.0699 | $1.764 | $2.015 | 784.62K |
| Oct 19, 2026 | $1.70 | $1.78 | $1.67 | $1.77 | 274.68K |
| Oct 16, 2026 | $1.67 | $1.715 | $1.62 | $1.69 | 449.34K |
| Oct 15, 2026 | $1.71 | $1.755 | $1.66 | $1.67 | 602.71K |
| Oct 14, 2026 | $1.81 | $1.87 | $1.71 | $1.745 | 620.86K |
| Oct 13, 2026 | $2.00 | $2.00 | $1.81 | $1.815 | 646.34K |
| Oct 12, 2026 | $2.14 | $2.14 | $2.00 | $2.02 | 291.65K |
| Oct 9, 2026 | $2.12 | $2.17 | $2.081 | $2.14 | 357.54K |
| Oct 8, 2026 | $2.09 | $2.135 | $2.0201 | $2.10 | 505.17K |
| Oct 7, 2026 | $2.02 | $2.17 | $2.00 | $2.10 | 623.09K |
| Oct 6, 2026 | $2.13 | $2.14 | $2.00 | $2.03 | 562.87K |
| Oct 5, 2026 | $2.04 | $2.16 | $2.015 | $2.13 | 713.98K |
| Oct 2, 2026 | $2.10 | $2.10 | $2.015 | $2.04 | 580.52K |
| Oct 1, 2026 | $2.22 | $2.29 | $2.07 | $2.07 | 833.41K |
| Sep 30, 2026 | $2.25 | $2.45 | $2.10 | $2.22 | 1.48M |
| Sep 29, 2026 | $2.30 | $2.42 | $2.22 | $2.245 | 1.09M |
| Sep 28, 2026 | $2.22 | $2.375 | $2.19 | $2.30 | 856.38K |
The latest Smart Investors Daily articles mentioning ABOS.
Company
Market Activity
Research & News
ABOS research
Company profile and research snapshot.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | BTIG | Buy | — |
| Sep 15, 2026 | Citigroup | Buy | — |
| Mar 26, 2026 | BTIG | Buy | — |
| Mar 16, 2026 | BTIG | Buy | — |
| Jan 27, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Jun 17, 2026
JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ:
Yahoo · Mar 3, 2026
NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), announced today one oral and two poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) taking place in Copenhagen. The presentations will highlight new
Benzinga · Mar 3, 2026
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD),
Benzinga · Jan 27, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABOS.
